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Uzbekistan inherited a hospital-based health system from the Soviet Union. We explore the health system-related
challenges faced during the scale-up of ambulatory (outpatient) treatment for drug-susceptible and drug-resistant
tuberculosis (TB) in Karakalpakstan in Uzbekistan. Semi-structured interviews were conducted with key informants of
the TB services, the ministries of health and finance, and their TB control partners. Structural challenges and resource
needs were both discussed as obstacles to the expansion of ambulatory TB treatment. Respondents stated need for
revising the financing mechanisms of the TB services to incentivize referral to ambulatory TB treatment. An increased
workload and need for transportation in ambulatory TB care were also pointed out by respondents, given the quickly
rising outpatient numbers but per capita financing of outpatient care. Policy makers showed strong interest in good
practice examples for financing ambulatory-based management of TB in comparable contexts and in guidance for
revising the financing of the TB services in a way that strengthens ambulatory TB treatment. To facilitate changing the
model of care, TB control strategies emphasizing ambulatory care in hospital-oriented health systems should anticipate
health system support and strengthening needs, and provide a plan of action to resolve both. Addressing both types
of needs may require not only involving TB control and health financing actors, but also increasing knowledge about
viable and tested financing mechanisms that incentivize the adoption of new models of care for TB.
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perceptions, Tuberculosis, UzbekistanIntroduction
Ambulatory-based management of tuberculosis (TB), in-
cluding multidrug-resistant tuberculosis (MDR-TB), ap-
pears to be effective and cost-effective in a variety of
settings [1–6]. With potential to increase the cost-
effective use of resources and to reduce the lag between
diagnosis and start of treatment, ambulatory treatment
of drug-susceptible as well as drug-resistant TB can help
improve quick and universal access to TB treatment,
which in turn mitigates the spread of TB in the* Correspondence: stefan.kohler@uni-heidelberg.de
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duce the risk of nosocomial TB transmission to hospital
staff and among patients, and it enables patients to re-
duce the costs associated with reduced time at work or
home [7–9]. The World Health Organization (WHO)
has encouraged outpatient TB management in resource-
limited settings since the '90s [10] and conditionally rec-
ommends ambulatory treatment of MDR-TB since 2011
[11]. The WHO reiterated these recommendations in its
post-2015 global TB strategy, labelled the End TB Strategy
[12], and has advised ambulatory-based management of
MDR-TB in all post-2011 Global Tuberculosis Reports
[13–16]:s distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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hospitalization, which should be limited to severe
cases.” (WHO End TB Strategy)“Greater use of ambulatory care as part of
decentralized PMDT [programmatic management of
drug-resistant TB] services is necessary to expand
access.” (WHO Global Tuberculosis Report 2015)
For the WHO European Region, a new TB action plan
was adopted in September 2015. It states that all WHO
high-priority countries for TB control in the European re-
gion should specify strategies and mechanisms for expand-
ing and maintaining ambulatory TB treatment by 2016
[17]. Presently, the treatment practices for TB involve high
levels of hospitalization in several high MDR-TB burden
countries. The hospitalization level of MDR-TB patients (at
least for part of the treatment) was between 75 and 100 %
in Eastern European countries, with the lowest levels in
Central Asia (30–40 % in Kazakhstan, Tajikistan and
Uzbekistan). The hospitalization level varied widely in the
African Region (21 % of patients in the Democratic Repub-
lic of the Congo to 100 % in Nigeria) [15]. Hospitalization
for 100 % of MDR-TB patients in 2013 was reported for
India, China and the Russian Federation, the three highest
MDR-TB burden countries in the world, and in 2014 for
China and the Russian Federation together with 8 other
high MDR-TB burden countries [15, 16]. Hence, many
more TB patients could and, based on the preliminary
evidence on effectiveness and cost-effectiveness of ambula-
tory MDR-TB treatment [2-6], probably should be treated
using ambulatory-based care rather than hospital-based care
in several high MDR-TB burden countries.
Uzbekistan has reduced the number of TB beds from
more than 15,000 in 2008 to less than 11,000 in 2012,
and decreased the duration of hospitalization for MDR-
TB patients from 270 to 90 days during the same period
[13]. In 2011, Presidential Decree No. 1652 [18] ordered
a further reduction of the number of state-funded hos-
pital beds, including TB beds. The decree instructed a
decrease in the number of buildings in the tuberculosis
care network from 152 (pre-2012) to 76, once fully im-
plemented [18, 19]. Notwithstanding this nationwide re-
duction in TB-bed capacity and the inclusion of
ambulatory-based TB care in the Uzbek strategy to
achieve universal access to TB treatment [20], the treat-
ment practice of TB remained hospital-based until Octo-
ber 2014 in all parts of Uzbekistan except for two
regions with pilot programs for ambulatory-based TB
care, the Republic of Karakalpakstan and Tashkent city.
The reason was Decree No. 160 and other prikazes (de-
crees) of the Ministry of Health (MoH) of Uzbekistan,
which required the treatment of all TB patients, other
than exceptional cases, to start in a TB hospital [21].Starting as well as continuing TB treatment on an am-
bulatory basis was permitted nationwide throughout
Uzbekistan on October 24, 2014, when the MoH of
Uzbekistan issued Decree No. 383 “On improvement of
TB care activities in the Republic of Uzbekistan” [22].
Decree No. 383 specifies groups of TB patients to be se-
lected for ambulatory-based treatment. These groups
consist of drug-susceptible and drug-resistant TB
patients with negative sputum smear status whose con-
dition does not require continuous monitoring, TB pa-
tients with uncomplicated active extrapulmonary TB,
TB-infected children without risk factors and, with per-
mission of a medical expert commission, exceptional
cases in which a sputum smear positive TB patient
wishes ambulatory treatment. In addition, the decree
states that sputum smear positive TB patient may be
treated home-based if adherence as well as specified cri-
teria for uninterrupted treatment and infection control
can be assured.
In Karakalpakstan, a republic in the northwestern part
of Uzbekistan, ambulatory treatment from day one has
been offered to patients with drug-susceptible and drug-
resistant forms of TB, including MDR-TB, already since
February 2011. The MoH of Karakalpakstan and Méde-
cins Sans Frontières (MSF) began implementing a pro-
gram, called “Comprehensive TB Care for All” [8], which
introduced rapid testing of drug-resistance and inte-
grated directly observed treatment, short-course (DOTS)
and DOTS-Plus treatment into a common ambulatory
TB care strategy for drug-susceptible and MDR-TB pa-
tients. The deviation from the national regulation that,
until October 2014, required hospitalization for at least
part of any TB treatment was made possible through De-
cree No. 39 of the MoH of Karakalpakstan, which gave
permission for ambulatory treatment of drug-susceptible
and drug-resistant TB from the day of diagnosis onward,
unless a patient’s poor health or socio-hygienic living
conditions require hospitalization [23]. The aim of the
“Comprehensive TB Care for All” program is to scale-up
the ambulatory TB care model until universal access to
TB treatment in Karakalpakstan is achieved [24].
Despite having established the regulatory basis for the
expansion of ambulatory treatment of drug-susceptible
and drug-resistant TB the incentives set by the Uzbek
health system, which finances hospitals based on their
bed occupancy, have been perceived to work against a fast
and full adoption of ambulatory-based TB care in Karakal-
pakstan. The experience of this setback has been described
in an MSF information booklet about the “Comprehensive
TB Care for All” program already at an early stage of im-
plementation [8]:
“Ambulatory [TB] care should be offered to all
patients from the very start of treatment, unless there
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Ambulatory treatment should generally be preferred
to hospital-based treatment because it reduces the
chance of cross-infection of hospitalized patients with
drug-resistant strains, and because it could likely
reduce adherence problems related to prolonged
hospital stays, such as the isolation of the patient from
their social environment. […] Presently, health system
financing in Uzbekistan is based on bed occupancy, on
the “per number of beds” principle. This creates
incentives for keeping patients in hospital for longer
than is necessary, which is exactly the opposite of the
desired situation. Instead, a system needs to be
introduced, with advice from appropriate experts in
health-system financing, which provides a proper
mix of incentives for good-quality treatment.” (MSF
information booklet “Comprehensive TB Care for All”)
The described problem of medically unnecessary hos-
pital stays is known as overhospitalization. It has been
discussed as an undesirable effect, in particular, in health
systems which once created a large hospital capacity,
such as those of former Soviet Union countries [19, 25].
While the general health sector has been and continues
to be reformed in several former Soviet Republics since
their independence, specialized health services, such as
the TB care sector in Uzbekistan, have usually not been
part of past health reforms and continue to work in the
traditional way with a few exceptions [26–28]. Unsur-
prisingly, overhospitalization of TB patients has been de-
scribed previously for post-Soviet states, for instance,
after ambulatory DOTS programs were introduced in
Russia [29, 30] or after the Stop TB strategy was imple-
mented in Armenia [31, 32].
Based on the Karakalpakstan experience, this study illus-
trates how the traditional financing mechanisms of the TB
services in the post-Soviet health system of Uzbekistan are
perceived as disincentives to the adoption of a compre-
hensive ambulatory care model for drug-susceptible and
drug-resistant TB. The study also shows that the perceived
challenges to scale-up of ambulatory TB treatment fit into
a classification of health system support and health system
strengthening needs. The health system strengthening and
support needs described by the study participants during
individual and group interviews exemplify the range of
challenges that can pose barriers to adopting comprehen-
sive ambulatory-based management of TB as recom-
mended by the WHO.
Background
TB and TB care in Karakalpakstan, Uzbekistan
Some of Uzbekistan’s highest TB burden occurs in its
northwestern part, the Republic of Karakalpakstan with
a population of 1.8 million people. In 2013, the TBprevalence in this region was 107.7 per 100,000 popula-
tion and the TB mortality was 10 per 100,000 population
according to MoH data. Multidrug-resistance rates were
40.8 % among new and 78.1 % among retreated TB cases
in 2010 [33].
The TB services are a specialized health service in
Karakalpakstan. They are governed by similar principles
as the Uzbek health system, which has evolved from the
Soviet Semashko model of health care. The government-
owned health system of Uzbekistan has been described
as strictly hierarchical, using predominantly policy for-
mulation as a mode of regulation. Subordinate levels of
the health system are expected to follow the policies set
by higher levels. Neither fiscal nor other forms of incen-
tives are traditionally used for the regulation of health
care providers [19, 34].
The TB services are budgeted by the treasury and op-
erated through the MoH. In the ambulatory sector, pri-
mary health care facilities are funded based on the
population of their catchment area, taking into account
its age and gender composition. Consequently, health fa-
cilities do not receive additional financial resources that
are directly tied to the growing number of outpatients
during the expansion of ambulatory TB care. Given the
per capita financing of outpatient care, the increasing
outpatient numbers resulted in an availability of fewer
resources per patient and a higher workload for the staff
of the ambulatory TB services, despite an indexed
budget that has grown. Hospital financing is based on
the annual average of inpatient bed numbers and bed
occupancy rates. Due to the bed-based funding, TB hos-
pitals that refer patients to ambulatory treatment risk
budget cuts. Past government decrees endorsed compre-
hensive ambulatory TB treatment and decreased the num-
ber of TB hospitals and beds available in Karakalpakstan
[23, 35], but no regulation changed the system-inherent in-
centives to hospitalize TB patients. The regulation and fi-
nancing mechanisms of the TB services in Karakalpakstan
and the incentives they set are discussed in more detail
elsewhere [27, 36] and are similar to those described for
Armenia prior to 2014 [26].
The TB services in Karakalpakstan have been collabor-
ating with MSF since 1998 to improve and expand TB
treatment. Initially a DOTS program was implemented
as a TB control strategy. The DOTS program had cov-
ered all districts in Karakalpakstan until August 2003.
Starting in September 2003, a DOTS-Plus program
added components for MDR-TB diagnosis, management
and treatment. All patients diagnosed with active drug-
susceptible TB and MDR-TB were admitted for an inten-
sive phase of at least 2 and 8 months of inpatient treat-
ment, respectively, or longer if needed to achieve
sputum conversion. The subsequent continuation phase
of treatment was administered through special DOTS
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patients. In the course of the scale-up of the DOTS-Plus
program, the management of drug-susceptible and drug-
resistant TB was integrated for the continuation phase.
Case detection, disease management and treatment were
fully integrated for drug-susceptible and drug-resistant TB
in 2010 (“Comprehensive TB Care for All”). Since Febru-
ary 2011, Decree No. 39 of the MoH Karakalpakstan
permits ambulatory intensive phase treatment of drug-
susceptible and drug-resistant TB, and to hospitalize select-
ively only those patients whose clinical condition or living
conditions require hospitalization [23]. Table 1 provides a
chronology of the TB control program in Karakalpakstan.
The TB bed capacity in Karakalpakstan was reduced
by more than 20 % (320 beds) from 2010 to 2014 based
on Decree No. 62 of the Cabinet of Ministers of the
Government of the Republic of Uzbekistan entitled “On
additional measures to decrease the incidence of tuber-
culosis in the Republic of Uzbekistan for 2011-2015”
[35]. Savings achieved by the downsizing of the inpatient
TB services were reinvested in the refurbishment and
modernization of the equipment of the TB hospitals
maintained. The MoH of Karakalpakstan plans to fur-
ther reduce the available TB hospital capacity, but the
MoH cannot reinvest savings from the inpatient TB ser-
vices into the ambulatory TB services under the finan-
cing mechanisms in place.Table 1 Chronology of the TB control program in Karakalpakstan, U
Date Activity
July 1998 First patient entered in DOTS program in Muynak d
June 2001 Launch of DST study
July 2002 First staff appointed to MDR-TB program (MDR-TB m
April 2003 Ministry of Health of the Republic of Uzbekistan issu
August 2003 DOTS expanded to the last uncovered district Turtk
September 2003 Start of DOTS-Plus program. First MDR-TB patients a
October 2004 Outpatient department opens in Nukus city for amb
May 2005 First MDR-TB patient cured
September 2005 Signed memorandum of understanding with Found
January 2006 GFATM TB program starts to supply second-line TB
October 2007 Ministry of Health of the Republic of Karakalpakstan
TB through early discharge into ambulatory care
May 2008 Ministry of Health of the Republic of Uzbekistan issu
August 2010 “Comprehensive TB Care for All” program approved
February 2011 Ministry of Health of the Republic of Karakalpakstan
expansion and management of TB [23]
March 2011 Cabinet of Ministers of the Republic of Uzbekistan i
TB facilities, and optimization of inpatient facilities t
December 2015 “Comprehensive TB Care for All” program implemen
DOTS directly observed treatment, short-course; DOTS-Plus is a management strateg
GFATM Global Fund to Fight AIDS, Tuberculosis and Malaria, MDR-TB multidrug-re
own compilationAmbulatory TB care is offered through DOTs corners
in polyclinics, primary health care facilities (Selskie Vra-
chebniye Punkti) and local health posts (former Feld-
sher-Accoucheur points) that operate as branches of the
primary health care facilities. In 2014, inpatient TB care
in the districts of Karakalpakstan was offered in seven
specialized TB hospitals, comprising rayon (district) and
inter-rayon hospitals. In addition, two Republican TB
Hospitals (No. 1 and No. 2) remained in Nukus City after
the closure of a third Republican TB Hospital (No. 3).
Each TB hospital has a smear positive and smear negative
ward, but only the Republican TB Hospitals in Nukus City
and an inter-rayon TB hospital in Chimbay treat drug-
resistant TB. Average costs of a hospital bed in Nukus City
in 2013 for a drug-susceptible TB patient were UZS
30,169 (USD 15) per day and UZS 1,206,756 UZS (USD
603) per case treated. The average length of stay was
40 days for drug-susceptible patients and 100 days for
patients with drug-resistant TB [9]. Cost or cost-
effectiveness estimates comparing ambulatory and
hospital-based treatment of MDR-TB in Karakalpakstan
are not available.
Before the “Comprehensive TB Care for All” program,
all MDR-TB patients had their treatment initiated in Re-
publican TB Hospital No. 1 or No. 2. In districts without
a TB inpatient department, patients were referred to the
regional capital city Nukus or to the closest districtzbekistan
istrict
edical doctor position)
ed Decree No. 160 on management of TB [21]
ul
dmitted to Republican TB Hospital No. 2 in Nukus
ulatory care of MDR-TB patients discharged from MDR-TB hospital
ation for Innovative New Diagnostics for rapid DST
drugs for Karakalpakstan
issued Decree No. 366 on expansion of ambulatory care of drug-resistant
ed Decree No. 180 on management of MDR-TB
in Karakalpakstan
issued Decree No. 39 on “Comprehensive TB Care for All” program
ssued Decree No. 62 on construction, reconstruction and refurbishment of
hrough abolition of low capacity inefficient TB facilities [35]
ted in all districts
y for MDR-TB built upon the elements of DOTS, DST drug susceptibility testing,
sistant tuberculosis, MSF Médecins Sans Frontières. Source: WHO [56] and
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treatment typically start their treatment in a TB cabinet
room and are then referred to the local outpatient pri-
mary health care facility. There is usually a TB cabinet
room or TB dispensary (a specialized ambulatory facil-
ity) in all districts. It is regularly attended by a TB doc-
tor, who is the only medical specialist with the authority
to establish an official diagnosis of TB.
Looking at the economic context, Uzbekistan has
faced steady economic growth over the past decade, and
government expenditures on health were predicted to
rise from 2.9 % of the GDP in 2010 to 4.4 % of the GDP
in 2020 [37]. The budget of the TB services has also
steadily increased over the past few years, with an an-
nual increase of approximately 30 %.
Cost and cost-effectiveness of treatment for MDR-TB
The cost per MDR-TB patient treated in Uzbekistan in
2014 was reported to be USD 2935 [16]. One systematic
review identified four studies on the cost and cost-
effectiveness of MDR-TB treatment in other countries
[3]. From the health system perspective, the cost (year
2005 USD) per disability-adjusted life-year (DALY)
averted through ambulatory-based management of MDR-
TB was estimated at USD 163 in Peru and USD 143 in the
Philippines (no and 7 days average hospitalization) com-
pared to USD 598 in Estonia and USD 745 in Tomsk. In
Estonia and Tomsk, treatment was hospital-oriented with,
on average, 192 days and 239 days of hospitalization, re-
spectively. The cost per patient for MDR-TB treatment
was USD 2423, USD 3613, USD 10,880 and USD 14,657,
respectively. Synthesizing the data from these four studies
and using probabilistic sensitivity analysis, the systematic
review also appraised the likely cost and cost-effectiveness
of MDR-TB treatment for 14 WHO subregions (covering
193 countries). Based on the model predictions, treatment
of MDR-TB in either model of care appeared highly cost-
effective in all 14 WHO subregions considered, according
to the WHO threshold that a health care intervention is
highly cost-effective if it costs less than the annual GDP
per capita per DALY averted [38]. The usefulness of the
WHO cost-effectiveness thresholds as a guide for policy-
makers is under debate [39], but the four studies reviewed
and the model predictions for the WHO subregions fur-
ther indicated a better cost-effectiveness for outpatient
versus inpatient models of care.
For the WHO subregion EUR B, which had an average
GDP per capita of USD 3384 and includes the Central
Asian republics Kyrgyzstan, Tajikistan, Turkmenistan
and Uzbekistan, cost per DALY averted were estimated
to be USD 316 (123–672) per patient treated ambulatory
and USD 801 (371–1,571) per patient treated hospital-
based. Cost per patient treated were estimated to be
USD 6,057 (2,955–11,692) in the outpatient model andUSD 15,505 (8,063–29,015) in the inpatient model, re-
spectively. These estimates from the probabilistic sensitiv-
ity analysis represent means with 5th and 95th percentiles
of the cost distributions. The systematic review and other
studies note that the main influences on cost are the
model of care and the drugs included in the treatment
regimen [3, 40, 41]. For patients, income loss often consti-
tutes the largest financial risk from TB [41, 42].
Health reform in post-Soviet states and financing of TB
services
There is a substantial body of literature on health reform
in Central Asia (Kazakhstan, Kyrgyzstan, Tajikistan,
Turkmenistan and Uzbekistan) and other regions of the
former Soviet Union [43–47]. Several post-Soviet states
have reformed the provision of services in primary
health care, and they have reduced the number of hos-
pital beds since independence. With a few exceptions,
the funding mechanisms for the specialized TB services
remained unchanged. In Armenia, new financing mecha-
nisms for both inpatient and outpatient TB services were
introduced in 2014, along with new criteria for hospital
admission and discharge. Bed-based financing for the in-
patient TB services has been replaced by fixed and vari-
able cost funding. Per-capita financing of the outpatient
TB services has been replaced by performance-based
funding. The new funding scheme also allows money
saved to be reinvested into an outpatient oriented TB
program and aims to produce a gradual shift of experi-
enced TB doctors from hospitals to outpatient services
[26, 27]. Belarus has started a pilot project in 2014,
under which money that became available after a reduc-
tion in the number of beds in one TB hospital would be
used to incentivize primary health care workers provid-
ing DOTS to rural outpatients [27]. Beginning in 2011,
the TB services have been reformed and integrated into
the primary health care in Georgia [28].
Theoretical framework
Supporting the health system can include any activity
that improves services. Support activities improve
outcomes primarily by increasing inputs. By contrast,
strengthening the health system is accomplished by
more comprehensive changes to policies and regulations,
organizational structures and relationships across the
health system building blocks. Strengthening activities
motivate changes in behavior and/or allow a more ef-
fective use of resources to improve (multiple) health ser-
vices. Hence, health system strengthening is about
making the system function better permanently, not just
filling gaps or supporting the system to produce better
short-term outcomes [48].
A wide spectrum of health system strengthening inter-
pretations exists. We adopted criteria suggested by Chee
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strengthening and support. If the questions in Table 2
could be answered with “Yes”, then coded interview con-
tent that related to a potentially needed activity or inter-
vention was classified as a health system strengthening
need, otherwise coded content was identified as a health
system support need.
Chee et al. [48] also require a fourth question to be
asked: “Do the interventions have cross-cutting benefits
beyond a single disease?” We did not apply this fourth
criterion because our study focused on the TB services,
which are organized and funded as a separate health ser-
vice with a disease-specific mandate within the general
health system in Uzbekistan.
According to Chee at al. [48] not distinguishing health
system support activities from strengthening ones can
lead to neglect of critical system strengthening activities,
as well as to unmet expectations of stronger health sys-
tems. They therefore argue that distinguishing between
these two types of activities will improve programming
impact.
Methods
Study setting and design
While making progress towards changing the model of
care for TB toward a decentralized ambulatory approach
since February 2011, MSF and the MoH of Krakalpak-
stan have noted that the existing health system financing
fails to incentivize the use of ambulatory-based TB care.
In response, this exploratory qualitative study was imple-
mented aiming to assess the policy for allocation of funds
for TB care in Karakalpakstan, the ways in which it under-
mines the implementation of decentralized ambulatory
care, and how the health financing could be changed to
support the expansion of ambulatory care for drug-sus-
ceptible and drug-resistant TB.
Interviews with one respondent and interviews with
several respondents were conducted between September
and October 2012 in Tashkent as well as in Nukus and
two districts of Karakalpakstan. Arrangements were
made to meet at a workplace convenient for all theTable 2 Is it Health System Strengthening?
Criteria to distinguish between health system strengthening and
support interventions
1. Do the interventions address policy and organizational constraints or
strengthen relationships between the six WHO [57] building blocks
of a health system (service delivery, health workforce, information,
medical products, vaccines and technologies, financing, and leadership
and governance)?
2. Will the interventions produce permanent systemic impact beyond
the term of the project?
3. Are the interventions tailored to country-specific constraints and
opportunities, with clearly defined roles for country institutions?
Source: Adapted from Chee et al. [48]participants in order for the interviews to be conducted.
During a typical interview, the questions progressed
from asking about the TB care financing in place,
through perceived challenges with respect to implement-
ing ambulatory TB care, to possible suggestions and so-
lutions. Open questions that subsequently became more
specific were asked within each topic. No prespecified
set of questions was used throughout due to the various,
usually natural settings in which interviews took place.
Study participants
Key informants with a high level of experience in the
provision, organization or financing of the TB services in
Karakalpakstan and/or the rest of Uzbekistan were iden-
tified and purposively contacted by staff of the Uzbek
mission of MSF who were familiar with the potential
participants. To learn about the views and perception of
various stakeholders, participants were selected from
the health and finance ministries, the TB services in
Karakalpakstan and from TB control partners (Global
Fund to Fight AIDS, Tuberculosis and Malaria; MSF,
Project Hope). A total of 24 unique respondents (including
authors AB, AK and NS) participated in 15 interviews. An
interview with more than one respondent was conducted
when more participants from the same group of partici-
pants could be met together. Group sizes varied from two
to five respondents. Two respondents participated in a
one-on-one interview and a group interview (Table 3).
Data collection
SK conducted all interviews. Interviews were either audio
recorded or written summary notes were taken by SK.
The majority of the conversations lasted between 45 mi-
nutes and 2 hours; two interviews lasted approximately
15 minutes. Interviews usually took place at the respon-
dents’ place of work, or, in one case, during a work-related
commute between health facilities. The commute was
chosen on purpose for one group interview with TB doc-
tors because the commute constituted a calm time among
peers during their work day. In eleven cases, an interview
was conducted in a local language and translation was
needed. Translation was provided by local MSF staff. A
translator was only present if translation was needed. In
five cases, one or two familiar people, such as colleagues
or MSF staff, were present but were not involved in the
core conversation. The number of discussions was not
predetermined. Data collection continued until the ideas
expressed were repetitions of concepts already identified,
that is, data saturation had been reached.
Data management and analysis
The data collected in individual and group interviews
were analyzed in the same manner using thematic ana-
lysis, a method for identifying, analyzing and reporting
Table 3 Study participants
Type of participant Affiliation Level Tool
Government official or employee Ministry of Health Uzbekistan Individual interview
Ministry of Health, Treasury or
government
Karakalpakstan Individual interviewa
2 x Group interviewa (2 participants
per group)
TB care provider TB services (inpatient and outpatient) Karakalpakstan 2 x Individual interview
4 x Group interviewb (2–3 participants
per group)
TB control partner GFTMA Uzbekistan Individual interview
Project Hope Uzbekistan Individual interview
MSFc Karakalpakstan and Uzbekistan 2 x Individual interviewd
Group interviewd (5 participants)
MSF Médecins Sans Frontières, GFATM Global Fund to Fight AIDS, Tuberculosis and Malaria, TB tuberculosis
a,dOne respondent participated in individual and group interview
bIncluded one city health department staff
cIncluded local and international MSF staff
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on organizing sections of the data into recurrent themes
and using quotes to illustrate the kind of data classified
within each theme [49, 50]. Data analysis began after the
first interview. The analysis was an ongoing process. Re-
cordings were listened to and notes were read through
several times to obtain a sense of the whole. Relevant
parts of the audio recorded English conversations or
the simultaneous English translations were transcribed
verbatim into written form using a text editor.
The data set used for the analysis was all text extracted
from the recording and notes. The analyst used codes to
identify explicit content that appeared interesting to him
regarding (financial) resources and incentives in TB care.
Reflecting on the pattern in the data, codes were collated
into potential themes. Thinking about the relationship
between themes, different levels of themes were divided
into main overarching themes and subthemes within
them. The analyst reviewed and refined the potential
subthemes and themes until he devised a satisfactory
thematic map, taking into account his review of related
literature and key documents. Finally, the analyst
checked whether the themes identified work in relation
to the coded extracts as well as the entire dataset. The
theoretical framework by Chee et al. [48] to distinguish
health system strengthening and support activities was
used in the derivation of the final themes. All manage-
ment and analysis was performed by SK.
Permissions
Permission to conduct the study was granted by the
MSF desk in Berlin and the MSF mission in Uzbekistan.
Potential study participants were contacted with infor-
mation about the study. An interview was scheduled
with those who agreed and were available to participate.
Interviews were recorded if permission was given andthe setting was suitable for recording. An opportunity to
revise the quotes reproduced was granted. Written
consent to reproduce the selected anonymized quotes
was obtained.
Results
A wide range of issues relating to the implementation
and expansion of ambulatory TB care was discussed.
Interview content that related to the financing of ambu-
latory TB care and its expansion was finally stratified
into three main themes: health system strengthening,
health system support and resources available. The focal
theme, health system strengthening, was further stratified
into two subthemes: financial disincentives to ambulatory
TB treatment and ideas for and enablers of change.
Health system strengthening
Financial disincentives to ambulatory TB treatment
Respondents reported the transition from hospital-based
TB care to ambulatory treatment is proving difficult, given
the financing of the TB services in Karakalpakstan. Three
major financial disincentives that hinder the scale-up of
ambulatory treatment were expressed.
Firstly, respondents explained that the funding of out-
patient TB care facilities is based on the population size,
age and sex composition of the area served. The re-
sources available for ambulatory TB care were perceived
as unresponsive to the increasing outpatient numbers
experienced during the scale-up. Decreasing resources
per patient and a higher workload for the staff of the
ambulatory TB services due to expanding outpatient
treatment of TB were described.
Secondly, the traditional bed-based financing of TB hos-
pitals has been perceived to undermine the transition to
mainly ambulatory TB treatment. The hospital financing
in place was described as a reason for continuingly high
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possibility to treat drug-susceptible and drug-resistant TB
patients as outpatients from the day of diagnosis in the
“Comprehensive TB Care for All” program districts.
“Going back to the beginning of last year, 2011, when
we got the approval from Karakalpakistan that we
could treat patients from day 1 on ambulatory care,
then shortly afterwards we realized there are two
forces which are working against each other. This issue
of how the government is financing the system became
so obvious. One force was that there is this prikaz
[MoH of Karakalpakstan Decree No. 39] which pushes
people into ambulatory care from day 1, so they are
not coming to the hospital. And the other force goes
against this, but you have to fill up your beds in the
hospital. So on the first day the doctors were agreeing
to treat the patient in an ambulatory way, and the
next day they grab the same patient, the same doctors
grab the same patient back into the hospital to fill up
the beds, because that is how they get the money.”
(Group interview 1)“The past practice was to finance the inpatient
facilities’ activities based on the number of the beds.
And one of the indicators of the medical facility
activity is to fulfill the plan of bed occupancy. In such
cases, you have to keep some patients longer than
necessary and not to discharge them from the hospital.
It is, therefore, the right decision to discuss the issue of
financing based on the number of patients. So,
irrespectively of where a patient is receiving his
treatment, the financial amount assigned for his
treatment will follow him.” (Interview 4)
Thirdly, respondents described separate budgets for
inpatient and outpatient TB services, and that funds al-
located to inpatient TB care, including savings from TB
bed reductions, cannot be reallocated by the MoH to the
expansion of ambulatory TB care. One respondent further
pointed out that the failure of the TB care financing to re-
ward successful treatment can also contribute to a high
rate of hospitalization of TB patients in Karakalpakstan:
“The treatment outcome does not really affect the
financing. So, it is a slight problem because if the
facility gets the funding according to the number of
the treated, like cured patients, then more focus would
be on the treatment outcome, successful outcome. It is
either cured or treatment completed. But as such
an approach does not work, so the facility is only
interested in having the beds occupied. Someone goes,
another one comes and fills in the bed. So it is not a
treatment outcome-oriented or patient-orientedapproach at all. So it is about occupying your beds.”
(Interview 2)Ideas for and enablers of change
While disincentives to the implementation of ambula-
tory TB treatment were repeatedly described in precise
and elaborate ways, only a few respondents put forward
ideas for alternative TB care financing mechanisms and
their suitability for the local context. Prompting for vi-
able options to modify the TB care financing in place,
case-based financing mechanisms, pay for performance
that gives financial incentives for better health outcomes,
and remuneration that is adjusted for the caseload and
the complexity of cases were all suggested as possible el-
ements of an alternative to the current funding of the
TB services. These ideas were expressed without an im-
plementation plan, for instance, describing that financing
of TB services should be for the actual number of cases
treated, should take into account treatment outcomes or
that salary should be according to the difficulty of the
job and depending on the number of patients.
Respondents were interested in training and real-life
examples on how to strengthen ambulatory TB care as a
specialized service in their health system. They indicated
that it would be useful to learn from the experience of
other countries, in particular post-Soviet states, which
have implemented financing reforms for their TB services.
“Because if it comes out and the state does not have a
real proof that it works, they may not change anything,
in the financing either. So I think they need proof at
a very high level like consultancy that it has worked
in similar settings, like other post-soviet countries,
because now almost everywhere the system is
unchanged.” (Interview 2)Health system support
The focus of the interviews conducted was to elicit
structural barriers in the health system that work against
the scale-up of ambulatory TB treatment. Nevertheless,
immediate resource needs also came up during the con-
versations, particularly if respondents were involved in
the day-to-day provision rather than the management or
organization of the TB services. The main needs re-
ported included a lack of ambulatory staff, due to an
increased workload resulting from the scale-up of ambu-
latory treatment, and a lack of transport capacity be-
tween facilities. Some respondents said that they knew
of ambulatory staff in the TB services who had paid out
of their own pocket for transportation or work-related
phone calls in the past because the resources provided
were sometimes insufficient.
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Responses in our study indicated an existing awareness
that health system strengthening needs to accompany
health system support within the TB services. In addition,
there appeared to be willingness to change the hospital-
based system and respondents shared a positive attitude
toward ambulatory TB treatment.
“There is certain interest in outpatient treatment from
all stakeholders, including the national partners.
We hear more and more about the possibility and
necessity to go more for outpatient care. Levels as high
as the ministry would also say the same. They are
looking for such a change, and they are looking for the
consultants to advise them on this, how to go through
this reform. This is the situation now.” (Interview 2)
Discussion
Most former Soviet Union countries have strong roots
in providing hospital-based TB care, and they had often
created a large capacity of hospital beds in a centralized
health care system. The traditional financing mecha-
nisms of the TB services, which continued to be in place
in Uzbekistan and other post-Soviet states after the dis-
solution of the Soviet Union, provide no incentives for
earliest possible referral to ambulatory care and fail to
reallocate resources towards the expansion of ambula-
tory TB treatment [36]. Interview participants in this
qualitative study in the context of the expansion of ambu-
latory treatment for drug-susceptible and drug-resistant
TB in Karakalpakstan described a range of health system
support and strengthening needs that were perceived as
barriers to changing the model of TB care.
The health system strengthening needs for the TB
services, which were enumerated during interviews, re-
sembles the common health system challenges of post-
Soviet Union states after their independence. Firstly, a
substantial proportion of medical treatment takes place
in hospitals that are financed based on bed numbers and
occupancy rates, despite the fact that several procedures
could probably be done efficiently and cost-effectively in
an ambulatory setting. Secondly, the ambulatory sector
needed for comprehensive outpatient care is underdevel-
oped and underfinanced [19, 46]. A further aspect related
to overhospitalization is specific to TB care, namely that
hospitalization of TB patients without sufficient isolation
poses a threat to the patients’ and medical staff ’s health as
it may cause infection with more resistant strains of TB
during treatment in hospital [51].
In the study context of Karakalpakstan, the stake-
holders involved in the organization and provision of the
TB services appeared committed and willing to change
the present TB care financing in order to implement
and scale-up ambulatory TB care. Positive attitudes ofkey stakeholders toward change help implement new TB
treatment strategies and may increase the pace of
change and the sustainability of change when achieved
[52]. However, the local public health decision-makers
interviewed described that lack of relevant evidence, best
practice examples or expert advice on desirable TB care
financing mechanisms hinders reforming the financing
of the TB services.
Few past health system strengthening activities have fo-
cused specifically on revising the traditional financing
mechanisms of the TB services in former Soviet states [26,
27], despite the fact that these financing mechanisms work
against the adoption of ambulatory TB treatment ap-
proaches. This may reflect that further operational and
health systems research for improving the performance
and introduction of new TB care delivery strategies is
needed [53]. As it may not be feasible to archive a reform
focused specifically on the financing mechanisms of the
TB services, health financing reform addressing inefficien-
cies, like overhospitalization, may need to be sought and
adopted in a broader context, taking into account special-
ized health sectors, such as the TB services in many post-
Soviet countries.
Health system changes that support the ambulatory
treatment model have already been achieved in
Karakalpakstan in an area other than financing of the
TB services. As ambulatory treatment of TB patients
uses more decentralized structures than inpatient treat-
ment, the clinical management has been decentralized.
Traditionally, every decision for each drug-susceptible and
drug-resistant TB patient went to a single consilium, the
medical expert commission authorized to make TB treat-
ment decisions, where each case is debated by specialists.
Meanwhile, most cases are reviewed by several mini consi-
lia within the districts. However, achieving this reform in
the health system has been described as difficult in an
MSF information booklet about the scale-up of ambula-
tory TB treatment [24]:
“Since 2011 there has been significant system change,
although achieving this has been a lengthy process
requiring the devolution of the decision making process
on TB diagnosis and care from a single, centralised
consilium to district level.” (MSF information booklet
“The Path to Scale-up”)
Strengths and limitations
The results of this study are subject to several limitations.
Some informants on the national level were unavailable
due to a busy working schedule. Not all interviews were
audio recorded and only notes were taken. The variety of
stakeholders interviewed facilitated broad rather than spe-
cific insights. Responses frequently involved centralized
decision-making and top-down regulation as a driver of
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study participants with the present system. Translators
were experienced with medical translation, but provided
real-time translation on partially new topics. In some in-
stances, the information and quotations translated may,
therefore, reflect content summaries rather than actual
wording. Interviewing more than one person at the same
time may have reduced the diversity of opinions. On the
other hand, interviewing a group can supplement inter-
viewing individuals, and it could have assisted respondents
to reevaluate a previous position or statement in need of
“amplification, qualification, amendment or contradiction”
[54]. We acknowledge that the variation in interviewing
methods limits the scope for understanding their individ-
ual strengths and limitations in our study context.
A coherent picture emerged across the individual in-
terviews and group interviews, but our findings may be
biased by the small study sample and lack of independ-
ent data. Three interview participants have been in-
volved in the conception and design of the study and
contributed to writing the manuscript. None of them
has been involved in data analysis and management. Fi-
nally, the interview partners were a selected group of re-
spondents with close ties to each other, many of whom
were involved in TB care and the scale-up of ambulatory
TB treatment. By contrast, the familiarity among the
relatively small number of key people involved with TB
care in Karakalpakstan ensured an in-depth coverage of
the local situation. We, therefore, believe that the in-
sights gained from this study are representative of the
health system strengthening and support needs experi-
enced by the TB services in Karakalpakstan in the course
of the scale-up of ambulatory-based management of TB.
Conclusions
Health systems may receive substantial support for effect-
ive TB control, but complementary health system strength-
ening can help to make adjustments to incentivize the
adoption of new treatment approaches, such as compre-
hensive ambulatory-based care of patients with drug-
susceptible and drug-resistant TB. The findings of this
study show that health system strengthening has been per-
ceived to be necessary for implementing and expanding
ambulatory TB treatment in Karakalpakstan, Uzbekistan,
notwithstanding the support received or requested. The
experience of Karakalpakstan illustrates the range of fac-
tors that may need to be considered to develop an effective
TB control strategy in post-Semashko health systems, and
that further research on improving the introduction of new
TB care delivery strategies is needed.
To facilitate the adoption of ambulatory models of
care, TB control strategies should anticipate both health
system support and strengthening needs, and the
possible consequence of involving health and financeministries, as well as TB control and health financing re-
form partners in the process of restructuring the model
of care for TB. Anticipating health system support and
strengthening might help identify key collaborators early,
which has been recommended as good practice in MDR-
TB program development and implementation [55].
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